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The administration of either phenobarbital or 3,4-benzpyreue to rats resulted in 
the rapid and marked induction of 6-aminolevulinic acid synthetase (EC 2.3.1.13), the 
proposed initial and rate-limiting enzyme in the hepatic heme biosynthetic pathKay. 
Enhanced formation of 6-aminolevulinic acid was followed sequentially by an en- 
hancement of t,he liver’s capacity to synthesize microsomal heme in viva, irlcreases irl 
the content, of cytochrome P-450 and protoheme in hepatic microsomes and stimula- 
tion of certain hepat-ic microsomal drug oxidations. 
Changes iu the hepatic microsomal levels of cytochrome P-450 paralleled, in part, 
changes in the activity of hepatic &aminolevulinic acid synthet,ase and in the ca- 
pacity of the liver to synthesize microsomal heme in vivo, suggesting that the rate of 
hepntic heme synthesis may control the rate of synthesis of hepatic microsomal cyto- 
chome P-450. Increases in the hepatic microsomal content of cytochrome bg, how- 
ever, followed a different time course from that observed from eit,her cytochrome P- 
450 or protoheme. 
The simultaneous administration of maximum stimulatory doses of phenobarbital 
and 3,+beuzpyrene did not result in an additive stimulation of &aminolevulinic acid 
synthetase activity, indicating that, phenobarbit,al and 3,Gbenzpyrene induce 6- 
aminolevulinic acid synthetase by the same or closely related mechanisms. However, 
the stimulatory effects of these agents on cytochrome P-450 and on the A-demethpl:t- 
tion of 3-methyl-4-monomet,hylaminoazobenzene were additive, suggesting that 
differences may exist in t,hc mechanism by which phenobarbital and 3,4-benzpyrene 
induce hepatic mirrosomal cytochrome P-450 and enhance certailr hepatic microsonral 
drug oxidations. 
Tre:ttmellt. of animals wit,11 certain drugs, 
such as phenobarbital, and carcinogens, such 
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as 3,4-benzpyrene, results in tlw enhanw 
merit, of the hepatic microsomal oxidations of 
many drugs and carcinogens (1, 2). Stimuln- 
tion of these oxidations appears to result, at 
least in part, from enhnncemrnt of lllr 
synthesis of cytoclrrome I’-450 (3, -I), tlw 
hepatic microsomal hemoprotein \vhich i?: 
considered to be the terminal oxidasc iti 
hepa,tic microsomal mixed-function oxida- 
tions (5, A). Recently, evidence 1~1s brwl 
presented which demonstrates tllnt man> 
agents, including phenobarbital and 3,4- 
benzpJ.renc, are capable of inducing hepat ic 
d-aminolevulinic acid synthetwsc (IX: 
410 
2.:2.1.13) (i-lo), the proposed initial :md 
ratvlimit ing enzyme in tlic lq:~tic licmr 
biosyntlic~l ic patliwy (11, 12). I<rh:~nced 
format ion of :Zl,iz” would lend to :m ill- 
crwsed rate of synthesis of licpatic heme 
\\-llicll in turn might result in the observed 
iticwaw in tile Iwpat ic microsomnl conterit 
of cytoclu~)mc P-350 arid in the stimulation 
of wrt xin hepat ic microsomal drug oxida- 
t ions. In :~ccord:tuce kvitli this proposal, 
~nwGous reports from this laboratory have 
tlcmonstr:itrd 1 hat enlianced hemc synthesis 
is rssent ial for the inductiou of q+ochromc~ 
I’-450 :ind the st~imuldiou of IicpaIic micro- 
~om:ll drug oxidations (10, 13). 
Tllc~ studies described iu the present report 
wrc rmdcrt &en in au attempt to elucidate 
t Ilr: r~htionship between the st imulatory 
vffect s of ~)llenobnrbit~al and 3,3-benzpyrene 
on llepat ic hemc synthesis and t,heir effect d 
on t lita hrpatic microsomal drug-metabolizing 
systrw. The rxistence of possible differences 
itI t 11~ mecllanism or mechanisms by \\-lAch 
I)llcw~b:rrbitnl and 3 ,$-benzpyrenc induce 
c~~tocllromc I’-~50 and enhance crrt:\in 
liepat ic microsomal drug oxidations W:IS 
:tlso rs:uniued. 
t ;Illc~c,~c~-(i-l,hosl)h:~t~,, ycas1 ~lllcose-C,~l’llos- 
phate dchytlrogcnasp, NAI)I”, NADPII (tylx 11, 
SAI)Tl (grade I I I), horse hrut cytwhrme c 
it vow I I I), :rrrd 3,-l-bpllzpyrene wpre obt :tinrd from 
Signu Chrrnical Cornl):tny. (;l,vci~~e-?-“C (al~~ilic 
wtivi t y 7.81 mCi/nnrnolc) was obtained from Kmv 
1~:11,ql:uld ?;rwlear Corporatiorl. l~:th~l~~lorphille 
hydrl,chloritle a11d norcodeiue hydrochloride wprc 
~,“r’~h:lSccl from Merck n11d c0111p:m!‘, IllC. ?-CFI:;- 
SIAU was :L generous gift from 1)r. J. A. ILIiller of 
1 he 3lchrtllc Laboratory for Ca~lcer I:psearch of 
The I:lrivrrsity of Wiscollsin, :tlltl :~clillorn~~in 1) 
was gct~r~o~~sly srlpl)lipd hy &Icrck :i11(1 Clornlxil~y, 
111~. .\lI other chemical and biwhprnicnls WVI’V 
~~ml~lo~~~d ill t hr highpst 1)“rity :~v:ril:rblc. 
nlillisterptl at :t dose of 40 rnp/kg, nhilc :(,GpIlz- 
pyrcne was dissolved ill corll oil tmd was xlrnillis- 
lewd :tt a dosr of 20 r&kg. These doses were 
foru~tl to l)rc~dllcr n~simrmr indllctivr c~ffccts. 
Control :ulirnnls rpwivetl all equal volrlrne of 0.9 h 
NaCl nlld/or cot71 oil. Actilloln~-tin 1) u-as dis- 
solved in prol)ylellp glycol and was :~dnrinistercd 
at :I dose of 3 my/kg. ,111 agents were adnlinistcred 
illtr:t1)pritone;rll?-. Itats were fasted for 21 hr llrior 
lo sacrifice bllt were given water at/ lihilu7~. In all 
experiments, the livers of at least two rats which 
receivpd ident ical I real rnpllls wcrc poolrd lllwn 
honlogenizal ioIl. 
Pt~eparatiotr 0J” 3f icroaows 
I::its wcrc s:rcrilicctl by dpcnpitatioll, :tnd the 
livers wprp pprftrspd in situ with ice-cold O.!)’ ; 
SnCl prior to c,scisioil. ;Z 25:; (a/v) hon~ogel~:ile 
wits prelx*‘etl in 1.15(‘;, KCI Ilsillg a I)ornlcc ho- 
mogenizer nit h :I loose ljestlp. Thp hon~ogen:tte 
was crrltrifrlgcd aI 9OOOg for 20 mill at O---l” ill a 
refrigprated Serwlll centrifllge lo sedimwlt tul- 
brokpn wlls, nllclei, rind mitorhondria. The 
l,“strrlitoc~llolltlri:rl slllwrll;rt:u11 w:is t hell celltri- 
I’rlged at 10.1,OOOy for 90 mill in a SI)illco Alodrl I, 
ul1r:icenl rii’rqy to wtlirwI~1 the rnicrc~sorn:~l fr:rc- 
tion. Thp nlicrosornid slrspellsio7ls t h115 prelxired 
wpre frpp of hernc~globill as rncas~lrcd by I he 
tnpt hod of Nishib:~ynshi alld S:lto (II). 
Methods for the deterrninatiorrs (11’ thr .Y- 
tlprnethyl:ltiolls of pth>-lmoyhinc :wd 3-CIl,- 
LIAB, thp O-tlrnleth?-l:~tic,rl of norcodeine, alrtl the 
activity of S:\I)PlI-cytochrorne c rctlllctast: in 
heImtic nlicrosomes havp been described l)revi- 
onsly (13). TIIP cot~tent of proleill, l)rotohenlr:, :LII~ 
cytochromes r-450 :uld I);, in 1 hr rnicrosomal SIX- 
lxrsiorrs wcrp tletrrminctl :w tiescribed l)rpviorwll 
(13). 
6.;llr/inolo’rrlinic: wit/ sUnihe(nae. The activity 
of ALA syllthpt ase wiis dctcrrninrd b), rnpa~uriug 
the rat P of format ion of ALA in heI)at ic homoge- 
nates nn~doyilig 3 niodificntion 01’ the nwlhotl of 
hl:rrver cl a/. (15). ltats were dccupitaletl, nlltl, 
aftpr in, si/u lxrfllaicnl of the livers, X3(, L (w/v) 
honic,gcn:ttcs werp ljrplxired in a 0.9: ; SaCl solu- 
t ioll c’ollt uillillg 0.5 InhI disotlirml Is:I~)TA and 10 
nih~ Tris-lIC1 bn(i’pr, l)FI T.4. Whcil livers from 
u)nt rol rals wprc‘ pml~lo~-cd, reaction mist u-es 
collt:Lined in :I tot al vol~uiic of 10 1111; 1 nlrnolt~ of 
glycirrc, 100 firriolrs of disodilm~ I<:1 )‘~A, 750 ~moles 
of Tris-HCl br~ll’er (pII 7.2), and 2.5 ml of homoge- 
nutc. Whell livprs from I,hcllol):~rbit:ll-i rpat ptl or 
3 ,~-l)cilzI’~rc’lle-l rpat etl rats w<‘rc crrll~loyc~d, 
rpnc.1 ion nlistllres rout :l.illed ill a total volmnc of 2 
ml ; 200 ~rnoles of glycainc, 20 ~rrwles of tlisotlitlnl 
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l<;I>TA, 150 pmoles of Tris-HCl buffer, pH 7.2, and 
0.5 ml of homogenate. Incubations were carried 
oul for 30 min in open, ‘&ml Erlenmeyer flasks at 
37” with shaking in a I)ubnolf metabolic incrtbator 
and were terminated by the addition of 0.5 ml of 
a 257; trichloroacetic acid (TC.4) solution per 2 
ml of reaction mixture. In order to subtract the 
endogenous ALA content of each liver, reactions 
were stopped at zero I ime by the addit ion of TCA. 
To measure t,he ALA formed in hepatic homoge- 
nates from control rats, 10 ml of the TCA super- 
natant was concentrated to 0.5 ml using a Burhler 
flask evaporator. After the addition of 1.5 ml of 
glass distilled water, 1 ml of the resulting sollltion 
was used for the detcrminat ion. When hepatic 
homogenates from phcnobarbit,al-treated or 3,4- 
henzpyrenr-treated rats were employed, 1 ml of 
the TCA supernatant was used directly for the 
determination. The method of Tschudy et al. (l(i) 
was used for the determination of A1,.4, except, 
that NaOH was omitted during the formation of 
the AL.4 pyrrolc. The reslllts described in the 
present report are comparable to those obt,ained 
when ALB synthetase activity was determined 
employing the more sensitive and specific method 
of Irving and Ellioli. (17). 
Heme in Vivo 
To study the liver’s capacit,y to synthesize 
microsomal heme in viva at various times after the 
onset of t,reatment with either phenobarbital or 
3,4-benzpyrene, rats received an intraperitoneal 
injection of 30 FCi of glycine-2-11C. After -15 min, 
rats were sacrificed by decapitation and livers 
were perfused with 0.9:; ?r’aCl to remove herno- 
globin prior to homogenization. Illcorporation of 
glycine-2-I% into hepat ic microsomnl heme was 
linear throl~ghout the 45.min pulse. Heme was 
extracted from t,he microsomal preparations using 
acid-acetone (13), and the protohemc content. and 
radioactivity of the ext,racted microsomal herne 
was determined as described previously (13). 
ItESULTS 
Efects of Phenobarbital and 3,4-Benzpyrene 
Treatments on the Activity of Hepatic 
&Aminoleuulinic Acid Syrrthetase 
As seen in Fig. 1, a single injection of either 
phenobarbit,al or 3,4-benzpyrene resulted in 
a rapid and marked increase in the act)ivity of 
hepaCe ALA synt,hetase. The magnitude of 
stimulation resulting from the administra- 
t,ion of 3,4-benzpyrene was about, 50 % of 
that observed after treatment with pheno- 
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FIG. 1. Effects of phenobarbital and 3,4- 
benzpyrene treatmenls on the activity of hepstic 
ALA synthetase. Rats received intraperitoneal 
injections of either phenobarbital (Pl3) (40 ma/ 
kg) or 3,4-benspyrene (BP) (20 mg/kg) at the 
times indicated by the arrows. Control animals 
received an equal volume of 0.9’$$ NaCl or corn oil. 
Snimals were sacrificed at the times indicated, anti 
the activity of ALB synthet.ase was determined ilk 
hepatic homogenates as described in the test. 
Each point, represents the mean of nt least 1 hrre 
experiments, and the brackets represent the 
standard error of the mean. The average control 
value was 16.0 mpmoles of ALA formed/g liver/hr. 
All points were significantly (I’ < 0.05) incre)ised 
over control values, except. the value obtained 2 
hr after the init ial administ,ration of 3,4-benz- 
pyrene 
tase activity became maximal approximatel> 
12 hr after the initial administrat,ion of either 
agent.. Once maximum stimulat.ion ~2s 
produced, however, t,he degree of enhance- 
ment of hepatic ALA synt,hetase activity 
declined, reaching a level 5 or 10 times 
greater than control values 120 hr after the 
onset of treatment with 3,4-benzpyrene or 
phenobsrbit-al, respectively. This decline ~-as 
not prevented by increasing the dose of 
either agent during the last 72 hr of the 
study, indicating that the apparent loss of 
stimulntory effect was not, due to decreases 
in the effective concentrations of thwe 
agents during the late Cme periods of this 
study. SimiIar pat.terns for the st-imulation of 
hepntic AT,A synthetase activity by pheno- 
barbital have been reported by Wada et al. 
(8) and by ;\ larver (9). 
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Granick (IS, 19) has suggested that t,he 
stimulation of hepatic AL,4 synt,hetase ac- 
t’ivit’y by compounds which enhance hepntic 
heme synthesis represents a true induction 
resulting from t,he increased cle HOUO synthesis 
of t,he enzyme Iyhich can be prevented by 
inhibitors of protein and TWA synt,hesis. As 
seen in Table 1, the stimulatory effects of 
both phenobarbital and 3,4benzpyrene on 
tile activity of hepstic AI,:2 synthetnse also 
appear to be due to ml induction, since t,he 
simultaneous administ~ration of actinomycin 
11 almost, completely prevent,ed any increase 
in the activit,y of .iLA synthetase following 
the administration of eit,her phenobarbital 
01 3,4--brnzpyrene. E’urt,hermore, when 
added in vitro to homogenates prepared from 
tile livers of control rats, neither plieno- 
barbit al ( 10e3 N) nor 3 ,4-benzpvrene (lo-” 
11) altered the activity of this enzyme, 
thereby indicat,ing that the stimulation did 
not result from an activation of :m already 
existing but, inactive form of AI,h synthe- 
tasc. 
Twatme,,ts on Hepatic Heme Sytdhesis 
in Vivo 
l’rcvious st,udies have demonstrated lhat 
treatment, of animals \vitli either plieno- 
barbit,al (7-9, 13, 30) or X,4-benzpyrene (10) 
results in the stimulation of the synthesis of 
hepatic microsomal heme. To study the 
relationship between the stimulat,ion of 
hepatic MA synthetase activity and t)hr en- 
hancement, of hepatic heme synthesis pro- 
duced by both phenobarbital and 3,4- 
benzpyrene, the incorporation of 30 &i 
pulse-dose of glycine-2J4C into hepatic 
microsomal heme was employed as ~~11 index 
of llepatic hemc synthesis ill oiw. In this 
manner, the capacit)y of the liver lo synthe- 
size microsomnl heme irt aillo XIS studied at 
various time intervals after tlic onset of 
trt~atment \Tith eit’her phenobarbital or 3,4- 
benzpyrene. As seen in Table II, the amount 
of radioactivity incorporated into micro- 
somal heme per gram of live ~2s signifi- 
cantly increased (P < 0.05) bekren S rind 
120 hr after the onset of treatment n-it11 
either agent, with maximum stimulation 







16.0 xt 1.2 
97.2 3~ 14.0 
12.0 * 2.1 
23.1 f 2.+ 
3,4-Benzpyrenc 
3, GBenzpyrenc + 
actinomycin I) 
u Eats received intraperitoned injections of 
artinomycin 11 (3 mg/kg) and/or either pheno- 
barbital (50 mg/kg) or 3 ,J-henzpyrene (20 mgjkgj 
al zero time. Control animals received nn equal 
volume of propylene glycol and/or either 0.99;. 
NaCl or corn oil. Four hours later, animals wertb 
sacrificed, ant1 the activiiy of ALA synthetaw 
was determined in hepntic homogenates as tlc- 
scribed in the t.ext. 
* I::ach vxlrw represents the mean f st;mdartl 
error of at lcas~ three experiments. 
c Values are significantly lower (P < 0.05) th:tlt 
the v:tlucs obtained after treat merit with phcno- 
barbit,al alone. 
occurring after approximately 48 hr. The 
incorporation of ““FeC13 kit,0 hepat#ic micro- 
somal heme in viva has previously been ob- 
served to be stimulated as early as 4 111 
aft,er t,he administration of phenobarbital 
(13). 
The stimulatory effects of phenobarbital 
and 3 ,4-benzpyrene 011 t,he liver’s capacity to 
synthesize microsomal heme in vivo appeared 
t,o parallel Iheir effects 011 the activity of 
hepatic AT,B synthetasr (Fig. I), although 
changes in the activity of this enzJ;me al,- 
pearcd to precede changes in hepat~c heme 
svnthesis it) ui~o. Furthrrmore, in agreement 
Ah the effwts of t,lirse agents on t Ilr 
activity of llepnt,ic ALA synthet aw, t Ile 
enhancement of hepatic heme synthesis i,~~ 
viw observed after treat,mcnt with :i ,I- 
bcnzpyrenc was approximnt~~ly 50 ‘2 of that, 
observed after thta administr:~tion of pllcwo- 
barbital. 
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IIours on 
treatment 
Percent of control” 
Phenobarbital 3,4-Benzpyrene 
.___ 
2 115 f 18 112 i 11 
4 110 i ti 107 zlz 5 
8 131 i 1Oc 118 zlz w 
12 217 f 29t 156 f 23c 
1G 2-10 Ik 1-4c 163 f w 
24 283 Ik 3l? 170 i 7’: 
18 32i dz lop 19i Z$Z Tr 
-, I” 243 I!z 18< 157 z!z 10’ 
96 188 f 11c 141 * 211 
120 173 i 18’ 141 f 21c 
.__~. 
” Phenobarbital (40 r&kg) or 3,Gbenzpyrene 
(20 m&kg) were admilristered intrapcritoneally to 
rats every 24 hr. Control animals received an 
eclual volume of 0.91; NaCl or corn oil. At. the 
times illdicated, rats received intrRperitorlc:rll~ a 
45.mill pulse-dose of 30 pCi of glycine-2-‘“C, and 
irlcorpor:ttiorl of isotope into extracted hcptic 
mic~rosomal heme was determined. The averqe 
col~t rol value was 7551 (‘pm in mirrosomul hemc 
per gram of liver. 
fj I~::rch valtle rcprcsellts t hc mean + standard 
error of at least three experiments. 
c P < 0.05. 
somal content of protohemt produced by 
3,4-benzpyrenc was approximately 50 % 
of t,llat, observed nftcr phenobarbital treat 
merit . 
In agreement with t’he observat,ions of 
other investigators (20P2), phenobarbital 
treatment resulted in an increased amount 
of microsomal protein per gram of liver 
(Table III). Treatment of rats with X,4- 
benzpyrene was also observed to result in an 
increased amount of microsomal protein per 
gram of liver (Table IV), although this 
st,imulat.ory effect. XLS not, very marked. 
Treatments on Hepatic Alicroso~mal 
Cytoctrwmes 
The effects of phenobarbital and 3,4- 
benzpyrene treatments on the content of 
cytochrome P-450 in liepat ic microsomes are 
summarized in lcig. 3 and in Tables III and 
IV. The amourlt of cytochrome I’-450 per 
milligram of microsomal prot,ein and pel 
gram of liver ws significantly increased 
(P < 0.05) S hr aft.er phenobarbital ndminis- 
tration aud 12 hr after the onset of 3,4- 
benzpyrene treatment. The amount, of 
cytochrome P-450 in IiepaCc microsomes 
Treatments OIL the Hepatic Microsonaal 
Coded of Protoheme ad Protein. 
Treatment of rats with either pheno- 
barbital or 3,4-benzpq’rene resulted in the 
elevation of l.he hepat tc microsomal content 
of protoheme as seen in Fig. 2 and in Tables 
III and IV. The amount of microsomal 
protoheme per milligram of microsomal 
protein and per gram of liver was signif- 
cantly increased (P < 0.05) 8 hr aft,er 
phenobarbital xdministrat,ion and 12 hr aft,er 
I he administration of 3 ,4-benzpyrene. Proto- 
hrme levels remained elevated during the 
remainder of‘ the st,udy, increasing to a 
maximum Y&96 hr after the onset of t,reat- 
men t, wit,h either agent , and theu declining 
Lo\vard control values during the last, 24 to 
AS IX of the study. In accordance with the 
effects of these agenls on t.he activity of 
Irrtpatic AU,A syrit.hetasc and hepatic heme 
~yt~tlicsis, increases in the hepstic micro- 
:: 0 8 16 24 48 86 
HOURS ON TREATMENT 
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Fro. 2. l?,fYec*is of phenobarbital and 3,l- 
benzpyrene 1 reatmcllts on the hepatic mirrcrsomal 
cont.ent of protoheme. Condit.ions were the same 
as desrribcd for Fig. 1. Each point. represents t.he 
mean of at, least three experiments. The average 
con1 rol vsl LIB was 1 .O(i mpmoles of prot oheme/mg 
protrirr. 




Protein Protoheme Cytochome Cytochrome P-450 ba 
, __ ~~-.___ ~~~~__ 
2 104 f 4 ‘119 f 19 112 * 8 ~114 i 17 
4 91 f 8 111 + 16 101 i 14 1101 zt 9 
8 94 f !) i128 i 5~ 132 f Iic illi f 13’ 
12 99 3~ i 139 It Rc 150 f 1oc ’ wi f (i 
16 103 i 9 II&! f (i’ 104 f 22r I111 f 12 
2-l 116 +C 17 177 + PW '200 f  31c ;103 % i 
48 131 f llc 250 zk 1V 349 * :?l2< 137 i llc 
72 145 i 10c 207 f lo< * 31c 110 f Jc 
96 176 i Jr X0 f 30r ‘488 , 05 f 46’ 157 i lSc 
120 170 i- 16’ 12% + lXc 377 f  3'7" 2‘Ll + 10” 
I ..-__ ~ 
‘1 Conditions were the same :ts desrribed for 
Fig. 1. The average control v;tllles were: protein, 
‘L1.7 mg/g liver; protohemr, 22.8 m~mr)les/g liver; 
pytochrome P-450, l.li Ol)r~o-rso ,,,,Jg liver; :lnd 
cytochrome b:, 4.iti m~moles/g liver. 
* Each valrw represents the mean + st all&d 
errnr of at least three experiments. 
r P < 0.05. 
Percent of control* 
Cytocllrome 
P-450 
124 zk 23 
09 i 10 
1Oi i 7 
138 i- 15c 
153 f 12’ 
Cytochrome ba 
112 zt 15 
Xi * 15 
100 i 11 
106 * 4 
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FIG. 3. I~Xfects of phellobwbital and :3,4- 
benapyrene treatments on hepat icv rnicrosom:rl 
levels of cytochrome P-450. Colttlit,ions were I he 
same as described for Fig. 1. I~:tlch point rcprescnts 
the mean of at least three experiments, alltl the 
brackets represent the standard error of the me:~n. 
The average control value was 0.05 OI).lin-l~a mr/ 
rng protein. 
then progressively increased until, about. 96 
hr after tbe onset, of treatment \vith either 
agent,, a maximum was reached. HOI+-ever, 
bchvecn 96 and 120 hr, the levels of cyto- 
chrome P-450 began t’o fall loward colll,rol 
values, although after 120 Ilr of i~rc:~tmcnt 
cyt,ochrome P-450 levels were iItcre:tsetl 
approximat#ely 3-fold by phenobarbital :I nd 
about Z-fold by 3,4-benzp~rene. Incre:~sing 
the doses of phenobarbital and X,4-btwz- 
pyrrne during the last 72 hr of thr: study did 
not prevciit cylochromr I’-450 lrvrls from 
declining after maximum stimulation RX+: 
achieved. The observation 11~1 :j ,4-bwlz- 
pyreneiuduced incrwsr in c~~tochrome I’-450 
levels was about 50 53 of that produwd b\- 
phenobarbital is cousistcwl \vit II I IIt, t~ll’t~~ s 
of lhrw agents 011 llle activity of Iiq~tic 
;iTA sgnt hct:tse, 11ept ic Iwnw synt ltcsis, 
and tllr lleptic microsomal contc~r~t 01 
protohcme. The rate: of I’-&50 iItcw:w in 
hepatic microsomes ;tft(tr. ~)henob:lrbit;d :ttl- 
ministration is similar to t 11nl obwrvr~tl by- 
01 hers (3, 30, 31). 
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FIG. 4. Effects of phenobarbital and 3,4- 
benzpyrene treatments on hepatic microsomal 
levels of cytochrome bs. Conditions were the same 
as described for Fig. 1. Each point represents the 
mean of at, least three experiments, and the 
brackets represent the standard error of the mean. 
The average control value was 0.22 mpmoles of 
cytochrome be/mg protein. 
microsomes did not increase during the first 
48 hr of treatment, although, as seen in Fig. 
4, the amount of cyt,ochrome b:, per milli- 
gram of microsomal protein did increase 
(P < 0.05) between 96 and 120 hr after the 
onset, of treatment wit,h either agent. How- 
ever, when the data were expressed as the 
amount’ of microsomal cytochrome b5 per 
gram of liver (Tables III and IV), significant 
increases (P < 0.05) were observed at about 
45 hr after the onset, of treatment, with 
phenobarbital and after 72-96 hr of 3,4- 
benzpyrene treatment. In agreement’ with 
the observations of other investigators (3, 9, 
23), the degree of enhancement of eyt.o- 
chrome b5 levels by t,hese two agents was 
considerably less t’ha,n t,heir effects on cgto- 
chrome P-450 levels. 
Effect of Phenobarbital a& 3,4-Benxpyrene 
Treatments 011, Hepatic Microsovnal Drug 
Oxidations and the Activity of Hepatic 
Xicrosomal NADPH-Cytochrome c 
Reductase 
The effects of phenobarbital on t,he hepatic 
microsomal demethylations of ethylmor- 
phine, norcodeine, and Y-CH$-MAB at, 72, 
96, and 120 hr after the onset of treatmeut 
are summarized in Table V. The stimulatory 
effects of phenobarbital on t.hese enzymatic 
reactions during the initial 48 hr of treat’- 
ment have been previously reported (13). 
As seen in Table V, both the specific activi- 
ties (rate per milligram of microsomal pro- 
i.ein) and the total activities (rate per gram 
of liver) of these reactions remained at a 
fairly constant level above control values 
TABLE V 
EFFECTS OF PHENOILLRBIT~LL ON HEP~TIC MICRO- 
SOMAL DRUG OXIDAIYONS .ZND THIS ACTIVITY OF 
HRP~TIC MICROSOS~~L XADPH-CTTOCHROME 
c REDUCTASE BT 72, 96, .&ND 120 Ha AFTER THE 
ONSET OF TREAYMENT~ 
/ 
Measurement 
Percent of controls 
HOWS 
on 
treat- Based .nc 
ment specific Based on 
activity total activity 
Ethylmorphine X- 72 267 f 25 436 f 37 
demethylation 96 284 f 45 430 + 38 
120 280 * 35 413 z!r 30 
Norcodeine O- / 72 147 f 18 226 XI= 25 
demet,hylation 96 149 f 23 228 f 14 
120 lF2 + 18 239 f 14 
3-CH,-MAB i\‘- 72 276 f 29 418 dz 21 
demethylation 96 258 zk 52 364 zk 27 
120 273 k 58 398 41 68 
KAL)PH-cytochrome 72 200 f 21 330 -f 31 
c reduct,ase 9G 211 f 39 320 zt 31 
120 227 ztz 21. 339 i 40 
a Rats received intraperitoneal injections of 
phenobarbital (40 mg/kg) every 24 hours, while 
control rats received an equal volume of 0.951 
NaCl. 
b Each value represents the mean =I= standard 
error of at least t.hree experiments. I’ < 0.05 for 
all values. 
c The average control values for demethyla- 
t,ions (mpmoles HCHO/mg protein/min) were 
3.42 for ethylmorphine, 0.95 for norcodeine, and 
0.67 for 3-CH,-MAB, while the average control 
value for NADPH-cytochrome c reductase was 
49.1 mpmoles of cytochrome c reduced/mg pro- 
tein/mill. 
d The average control values for demet.hyla- 
tions &moles HCHO/g liver/hr) were 6.00 for 
ethylmorphine, 1.71 for norcodeine, and 1.17 for 
3-CHa-MAB, while that for iYAI1PIIGcytochrome 
c redllctnse was 93.1 rmoles of cytochrome c 
reduced/g liver/hr. 
during these late time periods and did not 
decrease to\\urd control levels as did the 
hclpatic microsomnl cant ent of cyt ochrome 
I’-450 (l+$g. 3 and Table III). These observa- 
tions suggests Ilint, at, least after stimulation 
has occurred, the content, of cytochrome 
l’-430 in hepntic microsomes is of suficietit 
magnitude so as not to limit the hepatic 
microsomal oxidation of either ethJ4mor- 
phine, norcodeine, or SCH,-:\LhB. 
Tile effects of X,3-benzpyrene on the ac- 
tivity of hepatic microsomal SADI’H- 
cyt ochrome c reductase and the N-dcmet h- 
>,lntion of %CHa-:\lAB by hepntic micro- 
son~cs :at, 72, 96, and 1‘20 hr after the onset 
of treatment are summarized in Table VI. 
Tile effects of 3 ,kbenzpyrene on these rcac- 
tions during the init.ial 43 hr of treal merit 
have bee11 described previously (10). Al- 
t lwugh 3 ,i-benzp?rene did not stimulate 
lhe X-demethylatlon of et,hylmorphine 01 
the O~demetll?-lat,ioa of norcodeine by 
lwpatic microsomes (Table VII), the hepatic 
microsomal A-demet.hylation of %CH,- 
3 MI3 X\~M observed to increase progressively 
11111 il maximum st imuMion 1~~s achieved at 
approximately 72 1~ after the onset of treat- 
mcnt. Once maximum siimul~tion \vas pro- 
duced, N-demethylase activity remained 
const:ini al a level significant lg greater than 
control valtles. Unlike its effects on llte 
N-demethylstion of 3-CHa-NAB, 3 ,-l-benz- 
pyrene treatment did not result in a11 in- 
crease in the specific activity of S,L\l>I’H- 
cytochrome c reductase at a11~ time through- 
Percent of contrulb 
Hours on 
treatment 




AL.4 s~lltlwtase 12 290 + 51 133 rt 10 235 4z 14 
72 142 zk 28 71 zk 14 132 i 35 
Cytochromc P-450 72 3.66 f  0.33 2.4Y f 0.19 5.99 -f 0.58 
~-CIIZ-MAB ,~-demet.h~lation 72 4.43 42 0.44 3.76 f 0.77 7.76 f 0.93 
l~~~hglmorphine .V-demethylatiotl 72 22.22 zt 1.x 6.65 + 0.81 23.30: f 2.42 
Norcodeine 0-demethylation 72 3.72 + 0.60 1.81 4.Z 0.37 3.03 * 0.11 
NrZl>PII-c?-tocllrome c reductase 72 277 LIZ 25 123 * 15 302 It 47 
..-~-.~-. .~ - . .._ 
n I:ats received intraperitolleal injections of phenobarbital (40 mgkg and,or 3,4-benzpyrcne 20 
nlgskg) every 24 hr and were sacrificed at the times indicated. The average colrtrol values were ALA 
synthet,asr, I(i.0 mpmvles of ALA formed,‘g liver,/hr; cytochrome P-450, 1.31 aOD/g liver; NADPII- 
cptochrome c reducktse, 95.0 mpmolcs of cytochrome c reduced/g liver,/hr; ethylmorphine :V-de- 
mrth,vlatioI~ 6.05 mpmoles FJCIIO/g liverihr; norcodcille 0-demethglation, lY.C, /Imoles EJCIIO:g 
livcr,‘hr; and SCTJS-MAB ,\‘-demethylat,iorl, 1.17 pmoles TICTJO,/g 1iver;hr. 
j’ Itach vall~ represents t,he mean + standard error of at least three experiments. 
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out this study, although the activity of this 
enzyme per gram of liver was increased 
slightly at 72 and 96 hr. These observations 
are consistent with the view (10) that 
NADPH-cytochrome c reduct,ase may not, 
be tbe rate-limiting component in t,hose 
hepatic microsomal oxidations which are 
stimulated by 3.4benzpyrene. 
Although phenobarbit,aI and 3,4-benz- 
pyrene treat,ments both resulted in the en- 
hancement of hepatic ALA synthetase ac- 
t.ivity, liepatic heme synthesis, and hepatic 
microsomal levels of cyt,ochrome P-450, the 
observation that phenobarbital stimulated 
the hepatic microsomal demethylations of 
ethylmorphine, norcodeine, and NH,- 
1IAB and the activit>- of ,l-RDPH-cyto- 
chrome c redueta.se, while 3,4-benzpyrene 
had minimal effect on NADPH-cytochrome 
c reductase activit>- and stimulated the 
hepatic microsomal drmethylat~ion of 3-CH3- 
MAB only, suggests that more than one 
mechanism of induction may exist. Evidence 
supporting the vieis that different. mecha- 
nisms are involved in producing the stimula- 
tory effects observed when phenobarbit,al 
and 3,4-benzpyrene arc administered has 
come from skdies in which maximum 
st,imulatory doses of these agents are ad- 
ministered simultaneously to animals. These 
studies are ba,sed on the premise that, if a 
single inductjive mechanism is involved, then 
when either agent) is administered at a dose 
hewn to produce maximum st~imulation, 
the addit,ion of the other agent, should not, 
produce an additional response. If, on the 
other hand, different mechanisms are in 
valved. the sum of the maximum effects 
resulting when each agent, is employed alone 
would be observed when they are adminis- 
tered together. 
During t,hr initial s~udirs of this invest!i- 
@ion, the administration of phenobarbital 
at :L dose of 40 mg/kg and 3,4-benzpgrene 
at a dose of 20 mg,/l;g was found to produce 
maximum &imulation of the parameters 
studied. As seen in Table VII, t,he stimula- 
t or?: effects of phenobarbital and 3,4- 
benzpyrrwr on the act.ivitg of hepafic AT,A 
synf hetasr \vere not additive at, either 12 or 
72 hr after the onset of t,reat,ment. This ob- 
servation suggests that phenobarbital and 
3,4-benzpyrene st imu1nt.e hepatic ALA 
synthetase activity and thus result in the 
enhancement of hepatic heme synthesis by 
the same or similar mechanisms. However, 
in agreement with the findings of Sladek and 
J’fannering (4, %4), an additive response was 
observed in the enhancement of both cyto- 
chrome I’-450 levels in hepat,ic microsomes 
and the N-demethylation of %CH,-A\;lAB. 
No additive effects were observed on the 
hepatic microsomal demethylations of ethyl- 
morphine or norcodeine or on the act.ivity of 
hepatic microsomal NADPH-cytochrome c 
reductase, reactions which are not affected 
by 3,4-benzpyrene treatment. 
Treatment of rats with either pheno- 
barbital or 3,4-benzpyrene was found t,o 
result) in the rapid and marked stimulation of 
the activity of hepatic ALA synthetase, the 
proposed initial and rate-limiting enzyme in 
hepat,ic heme biosynthesis (11, 12). In- 
creases in the activit,y of this enzyme were 
observed as early as 2 hr after phenobarbital 
administration and 4 hr after the administra- 
t,ion of 3 ,4-benzpyrene. This st,imulat,ion 
appears to result from t,he increased c/e tlovo 
synthesis of ALA synthetase. i2lthough the 
magrmude of stimulation resulting from 
treat,ment- lvith 3 ,4-benzpyrene \vas approxi- 
mately 50% of that observed after pheno- 
barbital treatment, no additive stimulation 
of hepatic ALA synthet,ase activity was 
observed when animals were keated simul- 
t aneously with both agents. This observation 
suggests that phenobarbital and 3,4-benz- 
pyrene stimulate the synthesis of ALPL 
synthet ase by similar or closely relat,ed 
mechanisms. 
Stimulation of hepat,ic ALA synt hetase 
activity was closely followed by an in- 
creased incorporation of labeled lteme pre- 
cursor into hepatic microsomal heme in. viz!o. 
The enhancement- of the liver’s capacity t’o 
synthesize heme in vivo appeared to precede 
increases in the hepatic microsomal content 
of protohemr and cytochrome I’-450. 
Furthermore, the observat,ion that’ changes 
in the hepaGe microsomal levels of cyto- 
chromt: I’-4,50 folloned the ch:~ngw in the 
activity of hepntic ALA synthetnse and in 
1 hr capacity of the liver to synthesize micro- 
aomal heme i/h vivo suggests that heme 
synthesis may be the controlling event in t,he 
synthesis of hepatic microsomal cytochrome 
1’.350. In this respect, decreases in the 
degree of stimulation of hepntic MA synthe- 
tase activity, the liver’s capacity to synthe- 
size microsomal heme in viva, and cyto- 
chrome P-3.50 and prot,oheme levels in 
hcpatic microsomes observed during the l&e 
t.itne periods in these studies might be ex- 
plained on the basis of feedback repression 
of =\l,A s\-ntltctase by hcme as suggested b\ 
Grnnick (12, 19, 25). 
Although the hcpatic microsomal levels of 
cytocttrome I’-450 and protoltcmr: became 
elevnt cd during the initial 12 hr of 1 reAmeM 
if-it It either phenobarbital or 3 ,4-benzpyrene, 
tlw content of cytochrome b, in hepatic 
microsomcs remained urtchanged during the 
first 4s Itr of treatment. Tltese observations 
mn,v be explained on tltc> basis of the reln- 
1 iwty slo\\- turnover rate \vliich cytochromr 
bj has been observed to exhibit (‘26, Yi), 
since a slo\v rat c of turnover would result in 
a delayed appearance of a response to any 
changes in the rate of synthesis of the 
tiemoprot ein. 
The obscrvat,ions t,hat, phenobarbital 
t reatmcrtt resulted in the st,imulation of the 
ltepat ic microsomal oxidations of ethyl- 
morphine, norcodeine, and 3-CHa-!\IAB, as 
welt as n’ADl’H-cvtochrome c reductase 
activity, while 3.4.bettzpyrene treatment 
resulted in the stimulation of the N-demeth- 
J-lntion of 3-CH3-lllAB only, strengt~ltens the 
view that differences exist in the mechanism 
or mechanisms by which phenobarbital and 
3,4-bettzpyrerie stimulate the hrpatSic micro- 
somal drug-metabolizing q*stem. In accord- 
anct: n-ith this, and in agreement with the 
observut ions of Sladek and ,\I:rtutcring (4, 
24), the st imulat erg’ effects of phenobarbital 
and X,4-benzpyrcne on hepatic microsomal 
cytochrome P-450 and on the N-demethyln- 
tion of 3-CH3-RIAB mere additive. 
Sirtct: phenobarbital and 3,4-benzpyrene 
appear to st,imulate the activity of hepatic 
:\LA s!-nl.lietnse, and enhance liepatic heme 
synthesis by the same or closely related 
mechanisms, the results of these studies may 
b(, int tqret ed as indicating that the differ- 
ewes observed bet \\-een the stimulator> 
actions of phcnobnrbit at and 3 ,-l~btwzpyrrttc 
are due primarily to differences in the effects 
of these agents on the syntheses of crrt,nin 
hepntic microsomal proteins. This is cow 
sistent with the proposal that, the specks of 
cytochrome I’-450 induced by 3.4benz- 
pyrene and related compounds may be dif- 
ferent from that induced by phenobarbit:~l 
(4, 24, 28, 29). In accordance \vitlt this pro- 
posat, “cyt,ochromt~ I’-450” may act iiatlJ. 
consist, of a group of closely related cyto- 
chromes, each of which functions as a 
terminal oxidasc in the metabolism of a 
limit,ed number of substrates. Since certain 
protein moieties ma? confer different, 
specificities to q?oclirome P-450, 1 tic possi- 
bilit,y exist,s tjh:rt8 11lct differences observed 
between the stimulatory effects of plteno- 
barbital and :3 1 4-brttzpyrene may bc due to 
the differential st imutation of the s~.tttheses 
of these different :y,o”\,tocltromes. A1tlotjllt>t 
possibility lyhictt exists IS tllaf. several specific 
substrate-binding proteins rna~~ ftmct ion in 
the transport and positioning of substrates 
on cytocltrome I’-450, and phenobarbital and 
3 ,4-benzpyrcne may setect,iwly act ivat e 
and/or stimulate the syntllcsis of wme ot 
these proteins witttout ittflucttcittg others. 
A greater specificity in the t~nhancemertt of 
hepatic microsomal prot,eitt sJ.ttt hwis b;. 
3,4-benzpyrene may account for its lack of 
effect, on the hepntic microsomal osidntiotis 
of ethylmorphine on ttorcodeitte, as \velt as on 
the n&vi@ of hcpatic microsomnl SXDI’H 
cytocltrome c reductasr. 
Although ditirrenccs in the mechanisms 01’ 
st imiilal~iott appear to exist, the following 
sequence of evctttr can be postulated to 
occur during the complex process whicti 
ultimately results in the slimutntiott of 
certain hcpatic microsotm~l drug oxid:&tns. 
The administratiotr of an inducing agcttt 
such as pht:nobarbital or 3 ,4-bettzpywnct 
produces a rapid and marked increnw in t htl 
nct,ivity of hepatic Al,:1 syttthetaw Lvttictr. 
in t~urtt, results in llte twlt:ittcrnicttt of 
hepntic hetne synthesis. Stimulation of 
hepatic heme syttlllrsis leads to the ittcrtwt~d 
synthesis of hcpatic microsotmtl 0xicl:ktiotl:: 
of certain drugs and carcittogt~tts. 
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the increase in glycine incorporation into 
microsomal heme. Assuming that AT,A 
synthetase is rat,e limiting in hemc synthesis 
(11, l’r), this suggests that the activity as 
measured in vitro in the homogenat,e does not 
reflect funct~ional ALA synthetase activity 
Z’U ho. Several explanations are possible. 
About, 40 % of ALA synthetase activity after 
administration of allylisopropylacetamide 
(32, 33) is found in t,he cytosolic fraction of 
the hepatic cell. If increases of ALA synthe- 
tase after phenobarbital and 3,4-benzpyrene 
are also, in part, cytosolic it may be that this 
fraction of the enzymatic activity is not, 
functional due to inaccessability of succinyl- 
CoA. Indeed, we have found recent)ly thatf 
cytosolic ALA synthet,ase activit,y does in- 
crease after phenobarbital treat’ment (un- 
published observations), Anot,her possibilit#y 
is that, ALA synthetase act,ivity in vivo is 
under a certain degree of inhibit,ion from 
which it is released after homogenization. 
Recently, Scholnick et al. (X3) have shown 
that, soluble ALA synt,hetjase activity is 
inhibited by heme in h-o. However, in the 
present studies the pattern of increases and 
decreases of ALA synthetase activity after 
chronic administrntjion of phenobarbital 
and 3,4-benzpyrene is strikingly similar to 
that observed when heme synthesis was 
studied. 
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